HC Wainwright & Co. Reiterates Buy on ORIC Pharmaceuticals, Maintains $21 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Robert Burns has reiterated a Buy rating for ORIC Pharmaceuticals, maintaining a price target of $21.
September 18, 2024 | 5:33 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. has reiterated its Buy rating for ORIC Pharmaceuticals, maintaining a price target of $21. This suggests confidence in ORIC's potential for growth.
The reiteration of a Buy rating and maintenance of a $21 price target by HC Wainwright & Co. indicates a positive outlook on ORIC Pharmaceuticals' future performance. This can lead to increased investor confidence and potential upward movement in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100